Document Detail

An economic evaluation of tiludronic acid treatment in Paget's disease of bone.
MedLine Citation:
PMID:  10174312     Owner:  NLM     Status:  MEDLINE    
The objective of this study was to evaluate the long term comparative outcome of intermittent courses of therapy with low-dosage tiludronic acid (400 mg/day) versus etidronic acid in patients with Paget's disease of bone. The long term outcome was evaluated by means of a model, as the number of complications avoided during a 5-year period. Only major complications were considered (fractures of long bones, spinal cord dysfunction, osteoarthritis of the hip), which can be cured by adequate medical intervention, and may thus be valued in terms of direct costs. Deafness was not considered and was not valued. The various additional direct costs incurred (treatment and follow-up) and avoided (complications avoided) were assessed using an extrapolation model, based on the results of a clinical study. A standard costing methodology was used, according to the patterns of care currently in use in France. Costs were calculated from a societal perspective, including social security and private insurance fund reimbursements, and out-of-pocket expenses. These were estimated in French francs (F: 1994 values). The estimated mean treatment cost per patient for the treatment of Paget's disease and its complications over a 5-year period was F34,198 with etidronic acid, and F30,754 to F36,422 with tiludronic acid, depending on whether an optimistic or a conservative view of the efficacy of tiludronic acid was assumed. Despite its higher acquisition cost, the use of tiludronic acid was less expensive in the treatment of Paget's disease and its complications, compared with the use of etidronic acid, when an optimistic view of the efficacy of tiludronic acid was assumed.
A Lafuma; F Fagnani; P J Meunier
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  PharmacoEconomics     Volume:  12     ISSN:  1170-7690     ISO Abbreviation:  Pharmacoeconomics     Publication Date:  1997 Oct 
Date Detail:
Created Date:  1997-11-26     Completed Date:  1997-11-26     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9212404     Medline TA:  Pharmacoeconomics     Country:  NEW ZEALAND    
Other Details:
Languages:  eng     Pagination:  460-74     Citation Subset:  T    
CEMKA, Bourg-la-Reine, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Diphosphonates / economics*,  therapeutic use*
Double-Blind Method
Middle Aged
Models, Economic
Osteitis Deformans / drug therapy*,  economics*
Prospective Studies
Reg. No./Substance:
0/Diphosphonates; 89987-06-4/tiludronic acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The costs of epilepsy and cost-based evaluations of anticonvulsants.
Next Document:  Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and ...